

The Use of Mean Platelet Volume (MPV) in Differentiating Between Hyper Destructive Versus Hypo Productive Thrombocytopenia

Muhammad Faisal Bashir¹, Sidra Ghazanfer¹, Faiz Ahmed Faiz², Sarah Rafi³, Hasan Osman Mahmood⁴ and Khalid Aftab^{5*}

¹Assistant Professor Pathology, Khwaja M. Safdar Medical College (KMSMC), Sialkot, Pakistan

²Assistant Professor, Pathology, Islam Medical College, Sialkot, Pakistan

³Demonstrator, Department of Pathology, Rawalpindi Medical University, Rawalpindi, Pakistan

⁴Consultant Hematologist, Col.Sultan Lab, Sialkot, Pakistan

⁵Professor Pharmacology & CSO, Dr. Aftab Laboratories, Karachi, Pakistan

***Corresponding Author:** Khalid Aftab, Professor Pharmacology & CSO, Dr. Aftab Laboratories, Karachi, Pakistan.

Received: September 12, 2022; **Published:** October 14, 2022

Abstract

Objective: To establish the use of the mean platelet volume (MPV) as a tool in distinguishing between the hyper destructive versus hypo productive causes of thrombocytopenia.

Methods: This study was conducted at pathology department, Khawaja Muhammad Safdar Medical College, Sialkot (KMSMCS) from July 2020 to December 2020. Ethical approval was obtained from ethical committee of KMSMCS. 180 patients having platelet count less than $100 \times 10^9/L$ were enrolled. Patients were categorized into two groups:

1. Patients having thrombocytopenia due to increase destruction of platelets
2. Patients having thrombocytopenia due to reduced production of platelets.

Patients were selected from the CBC print generated by the automated haematology analyzer. Platelet count was manually verified by examining peripheral blood smear (PBS) on glass slides. MPV was recorded from the haematology analyzer print.

Results: 180 patients having platelet count less than $100 \times 10^9/L$ were enrolled. 87 were males and 93 were females. The male to female ratio was 1: 1.07. Age of the patients were between 0 - 88 years. Patients were further categorized into three groups on the basis of age. Group A (0 - 30 years), B (31 - 60 years) and C (61 - 90 years). Group B was the most common age group having 108 patients followed by group A which had 42.

Conclusion: MPV is a platelet parameter which is readily available, authentic and can be relied upon to help as regards the basic cause of thrombocytopenia. It is also more convenient for the patient as compared to the bone marrow examination.

Keywords: Mean Platelet Volume (MPV); Hyper Destructive; Hypo Productive; Thrombocytopenia

Introduction

The complete blood count (CBC) is a reflection of the hemopoietic activity showing the exact counts of the white blood cells and their differential, red blood cells and hemoglobin and platelets with their indices [1]. Platelets are derived from megakaryocytes and circulate in blood for 7 - 10 days [2]. Thrombocytopenia (platelet counts less than 150,000/ μ l) is routinely found in many disorders of the hemopoietic system [3]. Platelet levels below normal values confirm thrombocytopenia but they do not give a clue the underlying mechanism [4]. Advances in science and the use of automatic blood cell analyzers have led us to easily measure various platelet parameters. Platelet indices like the mean platelet volume (MPV), platelet distribution width (PDW), and platelet large cell ratio (P-LCR), may provide valuable clues [5]. Since immature platelets are large in size, a large number of these results in a higher MPV. The MPV is a part of the routine CBC with no extra added costs. Hence it is available along with the platelet count without any further testing required [6]. MPV is calculated as a measure of platelet volume expressed in femtoliter (fL). Normal range of MPV is reported to be between 7.2 and 11.7 fL. High MPV with ongoing thrombocytopenia represents peripheral destruction. Low MPV indicates underproduction/bone marrow suppression. MPV is in inverse relation to the platelet count [7,8]. Hence it is invaluable in differentiating between the hyper-destructive versus hypo-productive thrombocytopenia in a simple and reliable manner while being cost effective [9]. Additionally, it helps us to predict whether the thrombocytopenia will recover on its own thereby assisting in the clinical intervention of whether a platelet transfusion is needed or not [10-12].

Malarial infection also causes changes in platelet parameters hence the malarial parasite should also be ruled out [13]. Despite the numerous efforts that have been made as regards the clinical co relation of the platelet parameters, their definite link in terms of both diagnosis and prognosis, is yet to be fully proven [14,15]. This study is an attempt in adding to that knowledge and research.

Methodology

Centre of study: Department of Pathology, Khawaja Muhammad Safdar Medical College, Sialkot.

Period: July 2020 to December 2020.

Inclusion criteria: All thrombocytopenic patients having platelet count less than $100 \times 10^9/L$.

Exclusion criteria:

- Patients who have received platelet transfusion 7 days back.
- Patients who are not willing to participate in the study.

Materials and Methods

This study was conducted at pathology department, Khawaja Muhammad Safdar Medical College, Sialkot (KMSMCS) from July 2020 to December 2020. Ethical approval was obtained from ethical committee of KMSMCS. 180 patients having platelet count less than $100 \times 10^9/L$ were enrolled.

Patients were selected from the CBC print generated by the automated haematology analyzer. Platelet count was manually verified by examining peripheral blood smear (PBS) on glass slides. MPV was recorded from the haematology analyzer print. Falsely high MPV due to EDTA induced platelet swelling was avoided by running each sample as soon as it was collected. Investigations required identifying the cause of thrombocytopenia such as bone marrow examination, viral serology, drug history, vitamin B12 and red cell folate levels were recorded. Slides were also examined for malarial parasite in suspected cases.

Patients were categorized into two groups:

1. Patients having thrombocytopenia due to increase destruction of platelets.
2. Patients having thrombocytopenia due to reduce production of platelets.

Group A (n = 167) included cases of hypersplenism (n = 75), immune thrombocytopenic purpura (ITP) (n = 31), chronic kidney disease (n = 18) megaloblastic anaemia (n = 13), infection (n = 11), malaria (n = 8), neonatal thrombocytopenia (n = 4), gestational thrombocytopenia (n = 2) dengue (n = 1), drug induced thrombocytopenia (n = 1), hepatitis C virus (HCV) infection (n = 1), hepatitis B virus (HBV) infection (n = 1) and hepatocellular carcinoma (HCC) (n = 1).

Group B (n = 13) included cases of aplastic anaemia (n = 10) and acute leukaemia (n = 3).

Bone marrow examination was performed in all patients of group B (n = 13). Bone marrow findings confirmed the diagnosis.

Results

180 patients having platelet count less than $100 \times 10^9/L$ were enrolled. 87 were males and 93 were females. The male to female ratio was 1: 1.07. Age of the patients were between 0 - 88 years.

Patients were categorized into two groups:

1. Patients having thrombocytopenia due to increase destruction of platelets
2. Patients having thrombocytopenia due to reduce production of platelets.

Group A (n = 167) included cases of hypersplenism (n = 75), immune thrombocytopenic purpura (ITP) (n = 31), chronic kidney disease (n = 18) megaloblastic anaemia (n = 13), infection (n = 11), malaria (n = 8), neonatal thrombocytopenia (n = 4), gestational thrombocytopenia (n = 2) dengue (n = 1), drug induced thrombocytopenia (n = 1), hepatitis C virus (HCV) infection (n = 1), hepatitis B virus (HBV) infection (n = 1) and hepatocellular carcinoma (HCC) (n = 1) (Table 1).

Diagnosis	Patients
Hypersplenism	75
Immune thrombocytopenic purpura (ITP)	31
Chronic Kidney Disease	18
Megaloblastic anaemia	13
Infection	11
Malaria	08
Neonatal Thrombocytopenia	04
Gestational thrombocytopenia	02
Dengue	01
Drug induced thrombocytopenia	01
HCV infection	01
HBV infection	01
Hepatocellular carcinoma (HCC)	01
Total	167

Table 1: Patients in group A.

Thrombocytopenia due to increase destruction of platelets.

Group B (n = 13) included cases of aplastic anaemia (n = 10) and acute leukaemia (n = 3) (Table 2).

	Patients
Aplastic Anaemia	10
Acute Leukaemia	03
Total	13

Table 2: Patients in group B.

Thrombocytopenia due to reduce production of platelets.

In group A mean MPV was 11.03 ± 1.38 and mean platelet count was 66.52 (Table 3). In group B mean MPV was 8.53 ± 0.92 and mean platelet count was 51.77 (Table 4).

Diagnosis	Patients	Mean Platelet count x109/L	MPV fL, \pmSD
Hypersplenism	75	68.92	10.74 ± 1.55
Immune thrombocytopenic purpura (ITP)	31	62.39	11.86 ± 1.62
Chronic Kidney Disease	18	76.72	10.49 ± 1.19
Megaloblastic anaemia	13	47.92	10.89 ± 1.69
Infection	11	71.36	12.23 ± 1.04
Malaria	08	61.75	10.6 ± 0.96
Neonatal Thrombocytopenia	04	66.25	10.23 ± 0.95
Gestational thrombocytopenia	02	75.50	11.20 ± 0.14
Dengue	01	64	9.90
Drug induced thrombocytopenia	01	30	10
HCV infection	01	55	11.8
HBV infection	01	77	11.6
Hepatocellular carcinoma (HCC)	01	81	12.2
Total	167	66.52	11.03 ± 1.38

Table 3: Mean platelet volume in group A.

Diagnosis	Patients	Mean Platelet count x109/L	MPV fL, \pmSD
Aplastic Anaemia	10	58.80	8.62 ± 0.94
Acute Leukaemia	03	28.33	8.23 ± 0.95
Total	13	51.77	8.53 ± 0.92

Table 4: Mean platelet volume in group B.

Discussion

A study at Chiang Mai University Hospital, confirmed that since immature platelets are larger in size as compared to mature ones, the MPV measured using an automated hematology analyzer in cases of peripheral destruction is usually higher than in cases involv-

ing BM defects [16]. The findings of another similar study supported this hypothesis. In the validation cohort, where the causes of thrombocytopenia were confirmed by BM studies, the mean MPV in the over-destruction cohort was 10.4 fL compared to 7.2 fL in the underproductive BM group. The mean MPV in the over destruction cohort was close to a previous study (9.8 fL) [17].

A study conducted in Ethiopia showed that the MPV and P-LCR can better predict ITP in the initial stage and when the baseline investigations are being done [18].

A 2-year observational study which included 100 patients with thrombocytopenia was done in a single tertiary care centre. Results were noted for all patients in regards to their diagnoses, platelet counts and the MPV. The peripheral blood films were also examined for large platelets. The group with hyperdestructive causes demonstrated a total of 53 cases out of 79 having an MPV value more than 10.5 fL. Despite the fact the MPV was not significantly high in the remaining cases; the presence of large platelets was recorded on the peripheral film. The group with hypo-productive causes had 21 cases, none of which demonstrated a high MPV [19].

In a study by Kumari, *et al.* the mean MPV in the hypoproduction category was 10.6 ± 0.12 while that in the hyperdestruction category was 11.4 ± 0.89 with a P-value of < 0.0001 which is extremely significant [20].

Another study from India demonstrated a high MPV (10.46 fl) in the group with hyperdestructive thrombocytopenia in comparison with the hypoproduction group (8.7 fl) and the group showing abnormal pooling of platelets (8.15 fl) and with the control group (9.5 fl) [21].

The platelet indices are vital in differentiating between the mechanism of thrombocytopenia be it, decreased production or increased destruction. These platelet parameters are easily available and cost effective for the evaluation of thrombocytopenia [22].

In another study, MPV (11.51 ± 1.97) was higher in the category with increased destruction as compared to decreased production (8.34 ± 2) [23]. Similar findings were observed in a study by Mirza Asif Baig in pediatric tertiary care hospital [24].

In a study by Rajalakhshami RB, *et al.* the mean values of all the platelet parameters were higher in the category with increased destruction [PDW (16.6fL), MPV (12.1fL), P-LCR (42.3%)] as compared to the category with decreased production [PDW (11.8fL), MPV (10.9fL), P-LCR (31.5%)] [25]. The results were significant with a p value of < 0.05 .

Conclusion

Our study is in accordance with other studies showing that the MPV is a reliable indicator in differentiating between the hyperdestructive and hypoproduative causes of thrombocytopenia

Financial Aid

Nil.

Conflict of Interest

Nil.

Bibliography

1. Ashraf S, *et al.* "Comparison of Immature Platelet Fraction (IPF) in Patients with Central Thrombocytopenia and Peripheral Thrombocytopenia". *Journal of College of Physicians and Surgeons Pakistan* 30.08 (2020): 796-800.

2. Thiagarajan P. "Platelet disorders Overview of platelet disorders". Medscape (2020).
3. Basin TS., *et al.* "Changes in megakaryocytes in cases of thrombocytopenia: bone marrow aspiration and biopsy analysis". *Journal of Clinical and Diagnostic Research* 7.3 (2013): 473-479.
4. Strauss G., *et al.* "Immature platelet count: a simple parameter for distinguishing thrombocytopenia in pediatric acute lymphocytic". *Pediatric Blood and Cancer* 57 (2011): 641-647.
5. Elsewefy DA., *et al.* "Platelet indices: consideration in thrombocytopenia". *The Egyptian Journal of Haematology* 39 (2014): 134-138.
6. Chaves F. "Platelet morphology: reliable technology doesn't require duplication". *Medical Laboratory Observer* 44.8 (2012): 28.
7. Budak YU., *et al.* "The use of platelet indices, platelet crit, mean platelet volume and platelet distribution width in emergency non-traumatic abdominal surgery: A systematic review". *Biochemia Medica* 26 (2016): 178-193.
8. Kantharaj A. "Role of red cell and platelet indices as a predictive tool for transfusions in dengue". *Global Journal of Transfusion Medicine - DOAJ* 3 (2018): 103-108.
9. Islam S., *et al.* "Role of mean platelet volume (MPV), platelet distribution width (PDW) and platelet large cell ratio (P-LCR) value in the diagnosis of immune thrombocytopenic purpura". *Hematology and Transfusion International Journal* 2.2 (2016): 25-28.
10. Wandt H., *et al.* "Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study". *Lancet* 380 (2012): 1309-1316.
11. Estcourt LJ., *et al.* "Platelet transfusions for patients with haematological malignancies: who needs them?" *British Journal of Haematology* 154 (2011): 425-440.
12. Jeon Kibum MD., *et al.* "Immature platelet fraction: A useful marker for identifying the cause of thrombocytopenia and predicting platelet recovery". *Medicine* 99.7 (2020): e19096.
13. Jeon Kibum MD., *et al.* "Immature platelet fraction: A useful marker for identifying the cause of thrombocytopenia and predicting platelet recovery". *Medicine* 99.7 (2020): e19096.
14. TV Giovanetti., *et al.* "Platelet indices: laboratory and clinical applications". *Revista Brasileira de Hematologia e Hemoterapia* 33.2 (2011): 164-165.
15. Karolina Pogorzelska., *et al.* "Characteristics of platelet indices and their prognostic significance in selected medical condition – a systematic review". *Advances in Medical Sciences* 65.2 (2020): 310-315.
16. Norrasethada L., *et al.* "The use of mean platelet volume for distinguishing the causes of thrombocytopenia in adult patients". *Hematology Reports* 11.1 (2019): 7732.
17. Bowles KM., *et al.* "Platelet size has diagnostic predictive value in patients with thrombocytopenia". *Clinical and Laboratory Haematology* 27 (2005): 370-373.
18. Negash M., *et al.* "Diagnostic predictive value of platelet indices for discriminating hypo productive versus immune thrombocytopenia purpura in patients attending a tertiary care teaching hospital in Addis Ababa, Ethiopia". *BMC Hematology* 16 (2016): 18.
19. Gulati I., *et al.* "Diagnostic implication of mean platelet volume in thrombocytopenia". *Medical Journal of Dr. D.Y. Patil University - DOAJ* 10 (2017): 370-375.

20. Kumari KS, *et al.* "Analysis of platelet indices and its predictive value in diagnosis of thrombocytopenia". *Journal of Evolution of Medical and Dental Sciences* 7.26 (2018): 3023-3027.
21. Upadhyay J and Darad D. "Co-relation between mean platelet volume and the cause of thrombocytopenia: A hospital based study". *Indian Journal of Pathology: Research and Practice* 7.3 (2018): 33-339.
22. Mittal V, *et al.* "Study of platelet indices and their interpretation in thrombocytopenia in a tertiary care hospital". *Journal of Evolution of Medical and Dental Sciences* 10.07 (2021): 435-439.
23. Peddaverannagari T, *et al.* "Utility of platelet count and platelet indices in the evaluation of thrombocytopenia". *Journal of Evidence Based Medicine and Healthcare* 7.49 (2020): 2974-2980.
24. BAIG Mirza Asif. "Platelet indices- evaluation of their diagnostic role in pediatric thrombocytopenias (one year study)". *International Journal of Research in Medical Sciences* 3.9 (2017): 2284-2289.
25. Rajalakshmi RB, *et al.* "Evaluation of thrombocytopenia in megaloblastic anaemia by platelet indices and megakaryocytes comparison with hypoproduction and hyperdestruction". *National Journal of Laboratory Medicine* 6.1 (2017): 18-22.

Volume 10 Issue 11 November 2022

© All rights reserved by Khalid Aftab, *et al.*